Speakers

Claire D’Abreu-Hayling has over 35 years of experience as a pharmaceutical executive working in drug product development and global research and development. She is responsible for the global generics development network including infrastructure strategy, development capabilities, scientific pipeline execution and talent management. Claire also leads Clinical Development, Patient Safety, Regulatory Affairs and Global Device development enabling both generics and biosimilars development. Before joining Sandoz in 2021, she spent 15 years in senior roles at Teva Pharmaceuticals in the UK. She also worked with Sanofi and GSK early in her career. Claire D’Abreu-Hayling earned a bachelor of science degree in chemistry from the University of the West Indies in Trinidad & Tobago, as well as a master of science degree in pharmaceutical analysis and quality control from the University of London. She is a member of the board of directors of Black Phoenix Enterprise Ltd in the UK.